Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Calcipotriol
Accession Number
DB02300  (EXPT02131)
Type
Small Molecule
Groups
Approved
Description

Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Structure
Thumb
Synonyms
  • Calcipotriene
  • Calcipotriol
External IDs
MC 903 / MC-903
Product Ingredients
IngredientUNIICASInChI Key
Calcipotriol hydrateS7499TYY6G147657-22-5XBKHACNRWFKJNC-MANNPBRJSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DovonexSolution0.05 mg/1mLTopicalLeo Pharma1997-06-012013-04-01Us
DovonexCream50 ug/1gTopicalPhysicians Total Care, Inc.2006-09-15Not applicableUs
DovonexSolution0.05 mg/1mLTopicalPhysicians Total Care, Inc.2009-08-12Not applicableUs
DovonexCream50 ug/1gTopicalLEO Pharma Inc.1996-10-01Not applicableUs
DovonexOintment50 ug/1gTopicalWarner Chilcott2006-01-012007-04-01Us
DovonexSolution0.05 mg/1mLTopicalAllergan2006-01-012012-03-31Us
DovonexOintment50 ug/1gTopicalBristol Myers Squibb Pharma Company2009-06-012012-10-15Us
DovonexCream50 ug/1gTopicalAllergan2006-01-012012-03-31Us
DovonexOintment50 ug/1gTopicalPhysicians Total Care, Inc.2004-06-302010-12-29Us
Dovonex - Crm 50mcg/gmCream50 mcgTopicalLeo Pharma1995-12-312016-03-11Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalcipotrieneCream50 ug/1gTopicalPrasco Laboratories1996-10-01Not applicableUs
CalcipotrieneOintment0.05 mg/1gTopicalTaro Pharmaceuticals U.S.A., Inc.2010-03-24Not applicableUs
CalcipotrieneSolution0.05 mg/1mLTopicalFougera Pharmaceuticals Inc.2008-05-06Not applicableUs
CalcipotrieneSolution0.05 mg/1mLTopicalHi-Tech Pharmacal Co., Inc.2014-10-06Not applicableUs
CalcipotrieneSolution0.05 mg/1mLTopicalAmneal Pharmaceuticals of New York Llc2009-11-20Not applicableUs
CalcipotrieneOintment50 ug/1gTopicalGlenmark Pharmaceuticals Inc., USA2010-03-24Not applicableUs
CalcipotrieneCream50 ug/1gTopicalNorth Star Rx Llc2015-06-01Not applicableUs
CalcipotrieneOintment50 ug/1gTopicalPrasco Laboratories2013-07-01Not applicableUs
CalcipotrieneCream50 ug/1gTopicalGlenmark Pharmaceuticals Inc.,Usa2015-06-10Not applicableUs
CalcipotrieneSolution.05 mg/1mLTopicalGw Pharmaceuticals Ltd.2011-03-24Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%Calcipotriol (50 ug/1g) + Betamethasone dipropionate (0.5 mg/1g)OintmentTopicalSandoz2014-03-31Not applicableUs
Calcipotriene and Betamethasone DipropionateCalcipotriol hydrate (50 ug/1g) + Betamethasone dipropionate (0.5 mg/1g)OintmentTopicalPerrigo New York Inc2008-06-01Not applicableUs
Dovobet GelCalcipotriol (50 mcg) + Betamethasone (0.5 mg)GelTopicalLeo Pharma2009-01-28Not applicableCanada
Dovobet OintmentCalcipotriol (50 mcg) + Betamethasone (0.5 mg)OintmentTopicalLeo Pharma2001-11-29Not applicableCanada
EnstilarCalcipotriol hydrate (50 ug/1g) + Betamethasone dipropionate (0.5 mg/1g)Aerosol, foamTopicalLEO Pharma Inc.2015-10-16Not applicableUs
EnstilarCalcipotriol (50 mcg) + Betamethasone (0.5 mg)Aerosol, foamTopicalLeo Pharma2016-11-11Not applicableCanada
NuDermRxPAK 120Calcipotriol (50 ug/1g) + Dimethicone (50 mg/1mL)KitTopicalNucare Pharmaceuticals,inc.1996-10-01Not applicableUs
NuDermRxPAK 60Calcipotriol (50 ug/1g) + Dimethicone (50 mg/1mL)KitTopicalNucare Pharmaceuticals,inc.1996-10-01Not applicableUs
TaclonexCalcipotriol hydrate (50 ug/1g) + Betamethasone dipropionate (0.5 mg/1g)OintmentTopicalPhysicians Total Care, Inc.2010-10-20Not applicableUs
TaclonexCalcipotriol hydrate (50 ug/1g) + Betamethasone dipropionate (0.5 mg/1g)SuspensionTopicalLEO Pharma Inc.2008-06-012015-11-06Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcipotriene 0.005% / Clobetasol Propionate 0.05%Calcipotriol (0.005 g/100g) + Clobetasol propionate (0.05 g/100g)SolutionTopicalSincerus Florida, LLC2019-05-20Not applicableUs
Calcipotriene 0.005% / Diclofenac Sodium 3% / Hyaluronic Acid Sodium Salt 2% / Niacinamide 2%Calcipotriol (0.005 g/100g) + Diclofenac sodium (3 g/100g) + Sodium hyaluronate (2 g/100g) + Nicotinamide (2 g/100g)CreamTopicalSincerus Florida, LLC2019-05-07Not applicableUs
Calcipotriene 0.005% / Niacinamide 4%Calcipotriol (0.005 g/100g) + Nicotinamide (4 g/100g)CreamTopicalSincerus Florida, LLC2019-05-14Not applicableUs
Calcipotriene 0.005% / Triamcinolone Acetonide 0.1%Calcipotriol (0.005 g/100g) + Triamcinolone acetonide (0.1 g/100g)OintmentTopicalSincerus Florida, LLC2019-05-11Not applicableUs
International/Other Brands
Daivonex
Categories
UNII
143NQ3779B
CAS number
112965-21-6
Weight
Average: 412.6047
Monoisotopic: 412.297745146
Chemical Formula
C27H40O3
InChI Key
LWQQLNNNIPYSNX-UROSTWAQSA-N
InChI
InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
IUPAC Name
(1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol
SMILES
O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1

Pharmacology

Indication

For the treatment of moderate plaque psoriasis in adults.

Associated Conditions
Pharmacodynamics

Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin.

Mechanism of action

The precise mechanism of calcipotriol in remitting psoriasis is not well-understood, however, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor while being less than 1% the activity in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis and are believed to undergo modulation of gene expression with binding of calcipotriol to the VDR. This modulation is thought to affect gene products related to cell differentiation and proliferation.

TargetActionsOrganism
UVitamin D3 receptor
antagonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Clinical studies with radiolabeled ointment indicate that approximately 6% (+3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (+2.6%, SO) when applied to normal skin.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound.

Route of elimination

The active form of the vitamin, 1,25-dihydroxy vitamin D3 (calcitriol), is known to be recycled via the liver and excreted in the bile. There is evidence that maternal 1,25-dihydroxy vitamin D3 (calcitriol) may enter the fetal circulation, but it is not known whether it is excreted in human milk.

Half life
Not Available
Clearance
Not Available
Toxicity

Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
CalciumThe risk or severity of adverse effects can be increased when Calcium is combined with Calcipotriol.
Calcium acetateThe risk or severity of adverse effects can be increased when Calcium acetate is combined with Calcipotriol.
Calcium CarbonateThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcipotriol.
Calcium cationThe risk or severity of adverse effects can be increased when Calcium cation is combined with Calcipotriol.
Calcium ChlorideThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcipotriol.
Calcium CitrateThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Calcipotriol.
Calcium glubionateThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcipotriol.
Calcium glucoheptonateThe risk or severity of adverse effects can be increased when Calcium glucoheptonate is combined with Calcipotriol.
Calcium gluconateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcipotriol.
Calcium lactateThe risk or severity of adverse effects can be increased when Calcium lactate is combined with Calcipotriol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

Synthesis Reference

Andrzej Kutner, Michal Chodynski, Teresa Ryznar, Hanna Fitak, Jerzy Winiarski, Bartlomiej Gorecki, Agnieszka Burzynska, Wieslaw Szelejewski, "Process for Preparation of Pharmaceutically Pure Anhydrous Calcipotriol." U.S. Patent US20080214876, issued September 04, 2008.

US20080214876
General References
Not Available
External Links
Human Metabolome Database
HMDB0015567
KEGG Drug
D01125
PubChem Compound
5288783
PubChem Substance
46507122
ChemSpider
4450880
BindingDB
50369964
ChEBI
50749
ChEMBL
CHEMBL1200666
Therapeutic Targets Database
DAP000292
PharmGKB
PA448714
Guide to Pharmacology
GtP Drug Page
HET
MC9
Wikipedia
Calcipotriol
ATC Codes
D05AX52 — Calcipotriol, combinationsD05AX02 — Calcipotriol
AHFS Codes
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents
PDB Entries
1s19

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentActinic Keratosis (AK)1
0Not Yet RecruitingTreatmentActinic Keratosis (AK)1
0TerminatedBasic ScienceMorphoea / Scleroderma, Localized1
1CompletedOtherHealthy Volunteers1
1CompletedOtherPsoriasis2
1CompletedOtherPsoriasis Vulgaris (Plaque Psoriasis)1
1CompletedTreatmentPsoriasis3
1CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)3
1CompletedTreatmentPsoriasis / Psoriasis Vulgaris (Plaque Psoriasis)1
1CompletedTreatmentScalp Psoriasis2
1RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
1RecruitingTreatmentRefractory Neuroblastoma / Relapsed Neuroblastoma1
1TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
1WithdrawnTreatmentScleroderma1
1, 2CompletedTreatmentArthritis / Psoriasis1
1, 2CompletedTreatmentPsoriasis2
1, 2CompletedTreatmentPsoriasis / Psoriasis Vulgaris (Plaque Psoriasis)1
2CompletedTreatmentAtopic Dermatitis (AD)1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentHand Eczema1
2CompletedTreatmentPruritus / Psoriasis1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)6
2TerminatedTreatmentSickle Cell Disorders1
2Unknown StatusTreatmentRadiodermatitis1
2, 3CompletedTreatmentAcne Vulgaris1
2, 3CompletedTreatmentNail Psoriasis1
2, 3CompletedTreatmentPsoriasis1
3CompletedTreatmentPsoriasis1
3CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)4
3CompletedTreatmentScalp Psoriasis1
3Not Yet RecruitingTreatmentNail Psoriasis1
3Not Yet RecruitingTreatmentPsoriasis1
3RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
3WithdrawnTreatmentNail Psoriasis1
4CompletedOtherPsoriasis Vulgaris (Plaque Psoriasis)1
4CompletedSupportive CareAdherence1
4CompletedTreatmentPsoriasis3
4CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)4
4RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
4TerminatedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
Not AvailableCompletedNot AvailablePsoriasis Vulgaris (Plaque Psoriasis)1
Not AvailableCompletedTreatmentAlopecia Areata (AA)1
Not AvailableCompletedTreatmentChronic Plaque Psoriasis1
Not AvailableCompletedTreatmentPsoriasis1
Not AvailableRecruitingNot AvailablePsoriasis Vulgaris (Plaque Psoriasis)1
Not AvailableUnknown StatusTreatmentDermatitis, Allergic Contact1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Contract Pharm
  • Dispensing Solutions
  • E. Fougera and Co.
  • Glenmark Generics Ltd.
  • Hi Tech Pharmacal Co. Inc.
  • LEO Pharma Inc.
  • Nycomed Inc.
  • Physicians Total Care Inc.
  • Sandoz
  • Warner Chilcott Co. Inc.
  • WC Pharmaceuticals
Dosage forms
FormRouteStrength
CreamTopical0.05 mg/1g
OintmentTopical0.05 mg/1g
SolutionTopical.05 mg/1mL
SolutionTopical
CreamTopical
GelTopical
OintmentTopical
CreamTopical50 ug/1g
OintmentTopical50 ug/1g
SolutionTopical0.05 mg/1mL
CreamTopical50 mcg
OintmentTopical50 mcg
SolutionTopical50 mcg
Aerosol, foamTopical
KitTopical
Aerosol, foamTopical50 ug/1g
Spray, meteredTopical
SuspensionTopical
Prices
Unit descriptionCostUnit
Dovonex 0.005% Cream 120 gm Tube607.03USD tube
Dovonex 0.005% Solution 60ml Bottle323.98USD bottle
Dovonex 0.005% Cream 60 gm Tube303.51USD tube
Dovonex 0.005% cream4.23USD g
Dovonex 50 mcg/ml Solution0.84USD ml
Dovonex 50 mcg/g Cream0.83USD g
Dovonex 50 mcg/g Ointment0.81USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5763426No1998-06-092015-06-09Us
US6753013No2004-06-222020-01-27Us
US6787529No2004-09-072020-01-27Us
US8263580No2012-09-112028-09-27Us
US8629128No2014-01-142026-05-26Us
US9119781No2015-09-012031-06-10Us
US10130640No2018-11-202031-06-10Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0135 mg/mLALOGPS
logP4.63ALOGPS
logP3.84ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)14.39ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity125.45 m3·mol-1ChemAxon
Polarizability49.59 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9945
Blood Brain Barrier+0.8426
Caco-2 permeable+0.7643
P-glycoprotein substrateSubstrate0.7718
P-glycoprotein inhibitor INon-inhibitor0.7297
P-glycoprotein inhibitor IINon-inhibitor0.9687
Renal organic cation transporterNon-inhibitor0.813
CYP450 2C9 substrateNon-substrate0.8383
CYP450 2D6 substrateNon-substrate0.8975
CYP450 3A4 substrateSubstrate0.7113
CYP450 1A2 substrateNon-inhibitor0.7455
CYP450 2C9 inhibitorNon-inhibitor0.7898
CYP450 2D6 inhibitorNon-inhibitor0.9336
CYP450 2C19 inhibitorNon-inhibitor0.7994
CYP450 3A4 inhibitorNon-inhibitor0.8014
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7475
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9332
BiodegradationNot ready biodegradable0.9871
Rat acute toxicity3.9699 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9198
hERG inhibition (predictor II)Non-inhibitor0.8018
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Vitamin D and derivatives
Direct Parent
Vitamin D and derivatives
Alternative Parents
Triterpenoids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
Substituents
Triterpenoid / Cyclic alcohol / Secondary alcohol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Alcohol / Aliphatic homopolycyclic compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
seco-cholestane, hydroxy seco-steroid (CHEBI:50749) / Vitamin D3 and derivatives (LMST03020106)

Targets

Details
1. Vitamin D3 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
Gene Name
VDR
Uniprot ID
P11473
Uniprot Name
Vitamin D3 receptor
Molecular Weight
48288.64 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Sato H, Ogino Y, Takagi H, Hata J, Asano S, Ohta T, Komoriya K: Pharmacological profiles of high-concentration (20 microg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation, and differentiation in mice. J Dermatol. 2003 Jul;30(7):510-24. [PubMed:12928540]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity
Specific Function
Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can...
Gene Name
CYP24A1
Uniprot ID
Q07973
Uniprot Name
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial
Molecular Weight
58874.695 Da
References
  1. Jones G, Byford V, West S, Masuda S, Ibrahim G, Kaufmann M, Knutson JC, Strugnell S, Mehta R: Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs. Anticancer Res. 2006 Jul-Aug;26(4A):2589-95. [PubMed:16886668]

Drug created on June 13, 2005 07:24 / Updated on July 21, 2019 06:33